Tarsus Pharmaceuticals’ Q4 revenue rises 128% but EPS misses slightly
Tarsus Pharmaceuticals reported a fourth-quarter adjusted loss of $0.20 per share, compared with a $0.19 consensus estimate and a $0.60 loss a year earlier. Revenue jumped 128% year-over-year to $151.7 million, topping estimates by 4.6% and marking the fourth consecutive beat.
1. Q4 Financial Results
Tarsus recorded an adjusted loss per share of $0.20 for Q4 2025, missing estimates by $0.01 but improving from a $0.60 loss in Q4 2024. Consolidated revenue reached $151.7 million, up 128% year-over-year, driven by strong sales across key ophthalmic assets.
2. Estimate Surprise History
This quarter represents two EPS misses and four consecutive revenue beats over the past year. The slight EPS shortfall follows a prior quarter’s 14.3% positive surprise, underlining management’s success in driving top-line growth amid ongoing investment in R&D and commercial expansion.
3. Stock Performance and Outlook
Tarsus shares have declined about 18.7% year-to-date despite robust revenue growth. Investors will focus on upcoming management commentary for cost-control measures and the potential impact of late-stage trial data on profitability.